Your AI-Trained Oncology Knowledge Connection!
Mark Socinski, MD, is a medical oncologist and the executive medical director of the AdventHealth Cancer Institute in Orlando, Florida.
Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.
Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.
Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.
Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.
Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.
Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.
Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.
Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.
Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.
Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.
Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.
Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.
Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.
Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.
A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.
Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.
Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.
Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.
Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.
Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.
Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.
An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.
Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
A panel of experts debate the cost of innovation vs disruptive pricing of therapy.
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.
Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.
